NEWS: Our Blog

Alliance Pharma


Recent Posts

RESOURCES: 70th ASMS Conference on Mass Spectrometry and Allied Topics Posters

Jun 10, 2022 10:30:11 AM / by Alliance Pharma posted in Conferences, Posters

0 Comments


Alliance Pharma is proud to have presented the posters listed below at the 70th ASMS Conference on Mass Spectrometry and Allied Topics in Minneapolis, Minnesota USA.
June 5-9, 2022.

Click poster images below to download a PDF file.

 


An Ultra-sensitive, Robust and Fast Assay to Quantify Loteprednol Etabonate and
Ketorolac in Human plasma by SLE-UPLC-MS/MS

2021Posters_ASMS_1jpg

 



A Sensitive, High-Throughput Assay to Quantify Loteprednol Etabonate and Ketorolac
Tromethamine Using SLE-UPLC-MS/MS in Human Urine Treated with SDS

2021Posters_ASMS_2jpg

 



Characterization of the in Vitro Metabolic Profile of Abiraterone Acetate in cryopreserved Human Hepatocytes incubations by UPLC-Q Exactive Mass Spectrometry

2021Posters_ASMS_3jpg

 


 

 

 

 

Read More

RESOURCES: 2022 National Biotechnology Conference Posters

May 13, 2022 10:30:00 AM / by Alliance Pharma posted in Conferences, Posters

0 Comments


Alliance Pharma is proud to have presented the posters listed below at the AAPS National Biotechnology Conference in 2022.

Click poster images below to download a PDF file.

 


A Lesson Learned in Developing the Ligand Binding Assay for Quantification of Complement C3a

Alliance Pharma NBC 2022

 



Is Linear Regression Curve Fitting the Best Model for Stem-Loop RT-qPCR Data Analysis?

Alliance Pharma 2022 NBC Poster

 

Read More

AlliancePharma Announces Launch of Professional Services Quoting Application, PSQuote from CLD Partners

Apr 29, 2022 3:57:19 PM / by Alliance Pharma

0 Comments



MALVERN, Pa.,
 April 29, 2022 /PRNewswire/ -- This week, AlliancePharma (Malvern, PA) announced their go-live of PSQuote together with CLD Partners (Front Royal, VA). PSQuote is a newly developed professional services quoting application built on the Salesforce platform (PSQuote is a wholly-owned division of CLD Partners). AlliancePharma will use the tool to enhance and elevate their sales cycle, delivering a better customer sales experience--from quote to service delivery. CLD Partners has engaged with AlliancePharma since June 2021, for FinancialForce implementation services, and this new deployment is the next step in a growing business relationship.

AlliancePharma is a contract research organization (CRO) specializing in drug metabolism and pharmacokinetics (DMPK) and bioanalytical services for both small and large molecules. They serve clients throughout the development lifecycle, from pre-clinical/clinical trials to market entry. AlliancePharma works closely with their clients, allowing full access to data, creating strong partnerships and walks, side-by-side, with them through their project development.

Over the years, CLD Partners has built many custom professional services estimation tools based on the Salesforce platform, including for many large enterprises. They developed the expertise and experience from responding to a consistent request–how can a client more fully automate their quoting process and bridge the gap between their CRM and PSA (Professional Services Automation) tools.

With PSQuote deployed, AlliancePharma will now leverage the power of the Salesforce platform to centralize and standardize their quoting process, which will fuel their growth as they expand into other regions. Ryan Klein, Senior Director of Business Development and the executive sponsor for the implementation, said, "PSQuote is the right tool at the right time. We are aggressively scaling our organization to achieve growth goals over the next several years, and getting the right tools in place is key. We know PSQuote is going to grow with us, and we're grateful for CLD Partners' excellent implementation work."

CLD Partners CEO, Steve Clune, who originally designed PSQuote, sees this as a further step in CLD offering specific expertise to the CRO space. "Contract Research Organizations have unique challenges in transforming their workflows to a more automated and digital system. Through implementing FinancialForce with multiple CRO clients, including AlliancePharma, we have gained expertise in this space. And now, in deploying PSQuote, we're enhancing our solution offering to these organizations. I am excited to grow our practice for CROs even more."

PSQuote is a native Salesforce application available on the AppExchange

 

SOURCE CLD Partners

Read More

Alliance Pharma Appoints Patrick Bennett as Chief Executive Officer

Apr 12, 2022 4:51:57 PM / by Alliance Pharma posted in Leadership, CEO, Philadelphia, Patrick Bennett

0 Comments

Alliance Announcement of New CEO
Malvern, PA, March 25, 2022
- Alliance Pharma, a leader in small and large molecule bioanalytical services in the pharmaceutical and biopharmaceutical industry, announces that Patrick Bennett has been named Chief Executive Officer. Bennett has more than 30 years of experience in the industry, including 25 years in leadership roles at various bioanalytical contract research organizations, most recently as Vice President, Strategy and Development at PPD Laboratories. Prior to PPD, Bennett served as the Director of Global Strategic Marketing at ThermoFisher Scientific, and at various executive level positions with Tandem Labs. Frank Li, Founder of Alliance Pharma, is transitioning leadership to Bennett but will remain a key member of the Alliance team and serve as its President and on its Board of Directors. Throughout his career, Patrick has developed broad bioanalytical expertise and established a strong reputation as a leader and innovator in laboratory operations. In his most recent roles, he established biomarker, cell and gene therapy operations, and a state-of-the-art bioanalytical lab in China.

“Alliance will execute an aggressive global growth strategy, and there is no one more timely, skilled, or better suited to lead Alliance than Pat. His operational expertise, global experience, long-term relationship-driven nature, and exceptional communication skills are a perfect fit for Alliance” explained Dave Patteson, Chairman of the Board at Alliance and a Partner at Ampersand, Alliance’s principal owner.

“Frank Li has founded, built, grown and led an exceptional bioanalytical service offering and team of premier scientists, serving the pharma/biopharma industry. Our vision is to build upon this knowledge and experience, allowing Alliance to fulfill its mission as a complete global bioanalytical service provider for all drug modalities”, Patrick Bennett, New CEO of Alliance Pharma, commented.

 

About Alliance Pharma

Founded in 2008, Alliance is a contract research organization (CRO) in Malvern, PA just outside of Philadelphia that specializes in advanced bioanalytical research services for both small and large molecule drugs, as well as drug metabolism studies to support pharmaceutical and biotechnology companies’ drug discovery and development programs. Alliance’s mission is to build a trusted partnership with our clients to support their successful drug development programs. Our business philosophy is based on a foundation of trust, professional ethics, scientific excellence and regulatory compliance.

 

About Ampersand Capital Partners

Founded in 1988, Ampersand is a middle market private equity firm with more than $2 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm's core healthcare sectors. Additional information about Ampersand is available at ampersandcapital.com.

 

 

Read More

> University of Wisconsin Land O’Lakes DMPK Conference

Sep 6, 2019 10:00:00 AM / by Alliance Pharma posted in Pharmaceuticals, Conferences, DMPK

0 Comments

 


University of Wisconsin Land O’Lakes DMPK ConferenceThe Land O’Lakes conference series is one of the longest running and most revered teaching conferences in the pharmaceutical industry. Over the last two decades, the Land O’Lakes conferences have been developed by the division of pharmacy professional development within the school of pharmacy at the University of Wisconsin-Madison and have an impeccable reputation within the pharmaceutical industry for shedding light on cutting edge topics, bringing in knowledgeable experts and having an intimate setting which lends itself to some fantastic networking opportunities. 

We at Alliance Pharma are pleased to announce that we will be attending the 22nd annual Land O’Lakes conference on Drug Metabolism and Applied Pharmacokinetics on September 9th thru September 12th in Madison, Wisconsin. We are excited and eager to hear from industry leaders on the new advances in drug delivery, action and metabolism. This years’ meeting is titled ‘Found in Translation: Adaptive DMPK Strategies’, and will include topics focused on target mediated drug disposition (TMDD), endogenous biomarkers and more.


Target mediated drug disposition requires that we think outside the box in terms of drug distribution and elimination from the body. TMDD often exhibits nonlinear pharmacokinetics and pharmacodynamics due to the drugs unusually high affinity to a binding site.


Endogenous biomarker research, particularly in the drug transporter area, continues to rapidly evolve. Our biomarker team at Alliance is a highly experienced team with significant expertise in biomarker method development and analysis, yet we are always eager to learn more!


If you’re going to the conference and would like to meet with us, please contact Ryan Klein at rklein@alliancepharmaco.com or 919-801-3146.

Read More